Drugs in Context (Dec 2023)

Efficacy and safety of itopride SR for upper gastrointestinal symptoms in patients with diabetic gastroparesis: real-world evidence from Pakistan

  • Adil Ramzan,
  • Ghulam Fareed Memon,
  • Asif Ali,
  • Muhammad Masood,
  • Tariq Meher,
  • Adnan Ghafoor,
  • Naveed Ahmed Shehzad,
  • Safian Ahmed,
  • Zunaira Nawaz,
  • Muhammad Rehan,
  • Tariq Saeed,
  • Waqar Taj,
  • Sakhawat Abbass,
  • Ramiz Khan,
  • Hamza Ehsan,
  • Abubakkar Alam,
  • Bilal Manzoor,
  • Muhammad Nawaz Khan,
  • Khalid Mahmood Yahya,
  • Farhan Mukhtiar,
  • Muhammad Asif Javed,
  • Muhammad Usman Sheikh,
  • Danish Janjua,
  • Sumerah Jabeen,
  • Junaid Zafar,
  • Riaz Hussain Khokar,
  • Madeeha Nazar,
  • Neeta Maheshwary,
  • Muhammad Athar Khan

DOI
https://doi.org/10.7573/dic.2023-6-4
Journal volume & issue
Vol. 12
pp. 1 – 8

Abstract

Read online

Background: Gastroparesis is a serious condition that can be caused by diabetes, surgery or infection, or can be idiopathic. When there is no mechanical obstruction, gastroparesis is characterized by delayed stomach emptying. Itopride, a prokinetic drug, inhibits acetylcholinesterase activity in addition to antagonizing dopamine D2 receptors. Methods: This prospective, multicentre study is based on real-world data from 988 patients with a diagnosis of diabetic gastroparesis for index (PAGI-SYM2) evaluation at baseline and week 4 of treatment for upper gastrointestinal disorder symptoms. Results: Upper gastrointestinal symptom severity scores improved significantly after 4 weeks of treatment (p<0.001), with significant improvement across all categories of gastroparesis (very mild (37–58.6%), mild degree (24.6–31.6%), moderate (29.3–7.3%) and severe (8.8–2.6%). Conclusion: Itopride SR (Nogerd SR) in a 150 mg once-daily dose showed promising results in reducing the severity of upper gastrointestinal disorder symptoms associated with diabetic gastroparesis. Both statistical and clinical effectiveness were observed. Moreover, the treatment demonstrated a favourable tolerability profile, with a low incidence of adverse effects.

Keywords